ET Unwired: Reimagining Business | Webinars, Masterclass & WorkshopET Unwired: Reimagining Business | Webinars, Masterclass & Workshop
  • About Us
  • Prive
  • Webinars
    • Upcoming Webinars
    • Past UnWired Sessions
  • Masterclass
  • Roundtables
  • Contact

Towards Innovation: Bringing the Healthcare and Life Science World Together

unwiredcp2021-06-28T04:57:05+00:00

Technology plays an essential role in accelerating the distribution of the vaccine and evaluating, using global real-world data, how long the immunity lasts after vaccination to assess reinfection risks and determine when revaccination is necessary. The below section highlights on “How Innovation and Technologies are resulting as the Game Changer”

Emanation of synthetic biology:

Synthetic biology would predominate in coming years. It offers innovative approaches for engineering new biological systems or re-designing existing ones for useful purposes. It has been described as a disruptive technology at the heart of the so-called bioeconomy, capable of delivering new solutions to global healthcare, agriculture, manufacturing, and environmental challenge.

Promoting collaborations between academia and industry:

Collaboration is the key to successful to launch of drug products. There is need for initiatives to ensure effective industry-academia alliance

Development of personalized medicine through gene editing and biomaterial-based drug delivery systems:

Developing personalized medicine via gene editing (e.g., CRISPR) or biomaterial-based drug delivery systems are going to be trends in 2021

  • Innovative technologies to ameliorate/revamp scientific research
  • Increasing opportunities in adoption of automation platforms across pharmaceutical, medical device, and other life sciences businesses as it helps to enhance communications and processes to make supply chains more agile.
  • Robotic process automation (RPA), AI, and deep learning are among the emerging technologies that can drive fast-tracking early drug screens like image-based phenotypic profiling based on cell painting.
  • Expanding significantly is the proteomics segment where analysis can provide a complete depiction of functional and structural information of the cell and its response mechanisms to drugs and other foreign factors.

The key points of discussion would be around:

  1. Future-proof the foundation through modern platforms, modular architecture, and collaborations
  • How do we position Synthetic biology to meet the challenges of 2021 with respect to the risks and advantages?
  • Leveraging the industry academia collaboration around vaccine/mAbs research.
  • Development of personalized medicine through gene editing and biomaterial-based drug delivery systems
  1. Innovative technologies to ameliorate/revamp scientific research
  2. Logical thinking and design-based solutions to address medical challenges, rather than relying on serendipity or brute force processes
  3. Vaccine development and innovating technologies

Speakers

Dr. Himanshu Gadgil
Director & CSO
Director & CSO

Dr. Himanshu Gadgil, Dr. Himanshu Gadgil, Enzene Biosciences Ltd

Dr. Himanshu Gadgil serves as the Whole-time Director at Enzene Biosciences Ltd. presiding over all business functions of the company. Under his services, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service based biopharmaceutical company. Prior to Enzene, he worked as the Sr. Vice President at Intas Pharmaceutical Ltd. where he was instrumental in turning around the commercial product pipeline by launching several biosimilar products in multiple geographies. During his stint in the US, he led different facets of process and product development at Amgen spearheading IND, BLA and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation where he pioneered development of QBD enabling multi-attribute methodologies for biopharmaceutical characterization. Himanshu holds a PhD in Biochemistry from University of Tennessee and is a passionate scientific leader as well as innovator with over 50 publications and patents.
Close

Dr. Sanjay Singh
Chief Executive Officer
Gennova Biopharmaceuticals

Dr. Sanjay Singh, Chief Executive Officer, Gennova Biopharmaceuticals

Dr. Sanjay Singh is the Chief Executive Officer of Gennova Biopharmaceuticals Ltd, Pune, India, a biotechnology company dedicated to the development and commercialization of safe, efficacious, and affordable bio-therapeutics.

As a founder CEO, since 2006, at Gennova, Dr. Singh focused on innovations in bio-manufacturing technologies that culminated in the commercialization of seven life-saving bio-therapeutics in the cardiovascular, neurology, nephrology, and oncology market.

Under his leadership, his team pioneered the work that led to its approval of tenecteplase for Acute Ischemic Stroke (AIS) — the first time globally, securing global patents. The Department of Biotechnology (DBT), Govt. of India recognized this innovation for the ‘Biotech product, process development and commercialization award 2019’ and it found its way in the list of drugs for emergency care for stroke management in the guideline — ‘Prevention and Management of Stroke,’ issued by the Ministry of Health and Family Welfare, Govt. of India.

Under him, Gennova has directed their research to cater to vaccine development of neglected diseases, in particular Malaria, HPV, Leishmaniasis, and Tuberculosis, in partnership with various national and global organizations, including the NIH, US-FDA etc.

Dr. Singh is currently a member of various important committee of national relevance, which notable include the Scientific Advisory Board of the National Center for Cell Sciences (NCCS), Pune, Research Council of the Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, National Committee for Biotechnology- Confederation of Indian Industry (CII), New Delhi. Additionally, he is an invited member of the Indo-US Vaccine Action Program (VAP).

Contributing towards the national interests, Dr. Singh served as a member of the committee for the development of the India Guidelines on Similar Biologics (Regulatory Requirements for Marketing Authorization) constituted by the Department of Biotechnology (DBT), Ministry of Science and Technology (Govt. of India) and Central Drugs Standard Control Organization (CDSCO) and Ministry of Health and family welfare (Govt. of India). Contribution of this committee led to the establishment of a transparent path for successful development (clarity for Biotech Industry) and approval process (clarity of guidelines for regulatory agencies) to market the biosimilar drug product in India.

Dr. Singh holds a Ph.D. degree in Biochemistry from Central Drug Research Institute (CDRI), Lucknow, India. Before joining Gennova, he headed the Antigen Research Section at the Malaria Vaccine Development Unit of the National Institutes of Allergy and Infectious Diseases (NIAID), NIH, USA.

Close

Dr. Swapan Jana
Director of R&D and Manufacturig
Serum Institute

Dr Swapan Jana, Director of R&D and Manufacturig, Serum Institute

Dr. S.K. Jana is a Ph. D. on recombinant Hepatitis-B vaccine, an M. Tech. in Biochemical Engineering, B. Tech. in Chemical Technology, B. Sc. in Chemistry, PGDOM (Post Graduate Diploma in Operations Management).

University Gold Medalist, National Scholarship holder & GATE qualified, Govt. of India, SRF & JRF (DBT & DST). BEST Scientist & Employee award from Shantha Biotechnics Ltd. (A Sanofi group), Hyderabad, India.

Education: Calcutta University, Jadavpur University, Kolkata, IIT, Delhi

The last 30+ years in the fields of Biopharmaceuticals industry, Vaccine industry, Biosimilar product development at early stage, late stage development, pilot scale products development & commercial scale production, Upstream & Downstream Process Development, Bio-analytic methods development, Polysaccharide-protein conjugate vaccine, Technology Transfer, Project planning & execution. Extensive experience is in process & Technology development, optimisation, validation & Technology transfer.

Since December, 2008, I have been working with Serum Institute of India Pvt Ltd., Pune for the development of Pneumococcal conjugate vaccine + other vaccines.

Products developed by Dr. S K Jana & Team:

Lovastatin, rh-G-CSF, Hepatitis-B vaccine (r-HBsAg), rh-IFN-α 2b, r-Streptokinase, rh-Insulin, r-Erythropoietin (CHO cell line), rh-t-PA, DTP, ACP (Acellular pertussis-recombinant & non-recombinant), Hib conjugate vaccine, HPV (Antigen of 5 as a single polypeptide), DTP-HepB-Hib Penta valent vaccine of Diptheria, Tetanus, Pertussis, Hepatitis-B & Hib, live Cholera vaccine, MenX & Pneumococcal Polysaccharide Conjugate Vaccine.

Professional experience:
• Worked in Process Development in IIT, Delhi (Pilot plant) for fermentation & purification process development followed by Ph.D. for a short time & discontinued.
• Worked as Scientist & Senior Scientist with Dr. Reddy’s Research Foundation (DRF, Dr. Reddy’s corporate R&D) & Dr. Reddy’s Laboratories (DRL) for 7.5 years, Hyderabad
• Worked for 8.5 years as Manager, Senior Scientist, Principal Scientist & Head-Process Development in Microbial Fermentation, Cell Culture & Downstream with Shantha Biotechnics Limited (Sanofi group), Hyderabad.

Total industrial experiences: 30+ years
Patents filed & granted: 18 nos. (National & International Patents, US, EU, Japan, etc)
Papers publication: 9 nos.

Close

Vishwanth Swarup
Chief Operating Officer
Bharat Serums and Vaccines

MR. VISHWANATH SWARUP, COO-India Business, BSV

Vishwanath Swarup is a business leader with experience across emerging and developed markets. He has led businesses at Dr. Reddy’s, Abbott, Pfizer, Unilever, McKinsey and Max Bupa. He has a rich experience across the healthcare value chain in the areas of strategy, operations, sales and marketing with the objective of serving patients. He has successfully turned around business operations, managed alliances and developed high performing teams.
Close

Mr. Sudarshan Jain
Secretary General
Indian Pharmaceutical Alliance (IPA) Senior Advisor, APAX Partners
Moderator

Mr. Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA) Senior Advisor, APAX Partners

Sudarshan has a strong passion for healthcare and the education sector. Currently, he is the Secretary-General of the Indian Pharmaceutical Alliance (www.ipa-india.org), Senior Advisor – Apax Partners and Board member of multiple organizations. He is also the Chair of International Generic and Biosimilar Medicines Association (IGBA) for 2021. He has served in several leadership positions for over 40 years in Healthcare industry (Lupin, Johnson & Johnson, Piramal, Abbott) and was formerly the Managing Director at Abbott Healthcare Solutions.

His current Board engagements include Abbott India, Healthium Limited (Apax portfolio company), Indian Education Society (IES), Advisory Board of Narsee Monjee University, Mumbai (NMIMS). He is the Visiting Faculty at Indian Institute of Management (IIM), Ahmedabad. He has contributed in shaping the healthcare policy and improving access to healthcare in India.

Sudarshan is an Alumnus of St. Stephens College, Delhi University and Indian Institute of Management (IIM), Ahmedabad.

Close

Agenda

4:30 – 4:35

Opening by ET Edge

4:35 – 5.25

Round Table Discussion: Active Intelligence: Accelerating informed decisions
Active Intelligence has raised the bar for technology, giving traditional methods a run for their money. With real-time and analytics-ready data, it has sped up business processes and is assisting them in making rapid and informed decisions. In this session we will discuss how this technology is rapidly evolving and will touch upon the following topics:

  • How to tackle business problems using Active Intelligence
  • How data pipelines enable quick decisions
  • How can businesses begin to incorporate Active Intelligence
  • Business outcomes that Active Intelligence may help you accomplish
  • Helps in prompting immediate actions

5.25 – 5:30

Closing Remarks by ET Edge

Register Now

  • Hidden

Contact Us

  • Address: Lotus Corporate Park, 19th floor – 1902 and 1901, G – Wing, Off Western Express Highway, Geetanjali Railway Colony, Laxmi Nagar, Goregaon (East), Mumbai – 400063
  • Email: etunwired@et-edge.com

Recent Webinar

Modernizing Data Management

As organizations realize the benefits of digital and cloud transformation, it has resulted in a further increase in pace... read more

Unlock And Scale

There is no better approach to solving challenges than the famous saying “two heads are better than one. Harnessing the... read more

Innovation stories of India

read more

© Copyright 2020. All Rights Reserved. An ET Edge initiative. Refund Policy | Privacy Policy | Terms of Use | FAQs
  • About Us
  • Prive
  • Webinars
    • Upcoming Webinars
    • Past UnWired Sessions
  • Masterclass
  • Roundtables
  • Contact

Contact Us

  • Address: Lotus Corporate Park, 19th floor – 1902 and 1901, G – Wing, Off Western Express Highway, Geetanjali Railway Colony, Laxmi Nagar, Goregaon (East), Mumbai – 400063
  • Email: etunwired@et-edge.com

Recent Webinar

Modernizing Data Management

As organizations realize the benefits of digital and cloud transformation, it has resulted in a further increase in pace... read more

Unlock And Scale

There is no better approach to solving challenges than the famous saying “two heads are better than one. Harnessing the... read more

Innovation stories of India

read more